Wei Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Su has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Lin Ye
School of Materials Science and Engineering, Beijing Institute of Technology, Beijing 100081, China
11 shared publications - Zongjian Liu
Beijing Rehabilitation Hospital Capital Medical University Beijing China
9 shared publications Yuanyuan Ran
7 shared publicationsMengjie Wang
5 shared publicationsNing Li
5 shared publicationsGuiqin Tian
4 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
Anisotropy Driven Mechanotransduction Regulates Neural Stem Cell Differentiation to Promote Neural Repair after Ischemic Stroke
Highlights● Anisotropic MicroRods provide directional mechanical cues to regulate neural stem cell fate.● MicroRod anisotropy promotes cytoskeletal remodeling and neuronal differentiation.● N-cadherin/β-catenin mechanotransduction mediates anisotropy-driven neural differentiation.● MicroRod-mediated neural differentiation enhances synaptic reconstruction after stroke.● Engineering anisotropic microenvironments promotes functional neural repair after ischemic stroke
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAnisotropy Driven Mechanotransduction Regulates Neural Stem Cell Differentiation to Promote Neural Repair after Ischemic Stroke
Highlights● Anisotropic MicroRods provide directional mechanical cues to regulate neural stem cell fate.● MicroRod anisotropy promotes cytoskeletal remodeling and neuronal differentiation.● N-cadherin/β-catenin mechanotransduction mediates anisotropy-driven neural differentiation.● MicroRod-mediated neural differentiation enhances synaptic reconstruction after stroke.● Engineering anisotropic microenvironments promotes functional neural repair after ischemic stroke
- Open Access
- 11 July 2026
- Published by Elsevier in SSRN Electronic Journal
Anisotropy-Driven Mechanotransduction Regulates Neural Stem Cell Differentiation to Promote Neural Repair after Ischemic Stroke
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, and the therapeutic efficacy of neural stem cell (NSC) transplantation remains limited by poor cell retention and insufficient neuronal differentiation. Here, we propose a geometry-driven biomaterial strategy to regulate NSC fate without exogenous biochemical cues. Using microfluidics, we fabricated shape-defined gelatin methacrylate/polyethylene glycol diacrylate (GelMA/PEGDA) hydrogel microparticles with tunable stiffness, including spherical (MicroSpheres) and rod-shaped (MicroRods). Compared with the stiffness regulation, particle geometry exerted a more prominent influence on NSC differentiation. Soft MicroRods, in particular, promoted iNSC elongation and neuronal differentiation into mature neurons. In a photothrombotic stroke mouse model, MicroRod-assisted transplantation significantly improved iNSC retention, enhanced neuronal differentiation, increased synaptic formation, and resulted in superior functional recovery compared with MicroSphere-based delivery. Mechanistically, RNA sequencing and experimental validation revealed that MicroRods promoted nuclear localization of β-catenin by inducing its dissociation from N-cadherin complexes. Inhibition of β-catenin nuclear transcription attenuated neuronal differentiation, confirming its critical role in geometry-mediated mechanotransduction. Collectively, this study identifies particle geometry as a key regulator of NSC fate and provides a effective strategy for enhancing neural regeneration after ischemic stroke.
- 11 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAnisotropy-Driven Mechanotransduction Regulates Neural Stem Cell Differentiation to Promote Neural Repair after Ischemic Stroke
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, and the therapeutic efficacy of neural stem cell (NSC) transplantation remains limited by poor cell retention and insufficient neuronal differentiation. Here, we propose a geometry-driven biomaterial strategy to regulate NSC fate without exogenous biochemical cues. Using microfluidics, we fabricated shape-defined gelatin methacrylate/polyethylene glycol diacrylate (GelMA/PEGDA) hydrogel microparticles with tunable stiffness, including spherical (MicroSpheres) and rod-shaped (MicroRods). Compared with the stiffness regulation, particle geometry exerted a more prominent influence on NSC differentiation. Soft MicroRods, in particular, promoted iNSC elongation and neuronal differentiation into mature neurons. In a photothrombotic stroke mouse model, MicroRod-assisted transplantation significantly improved iNSC retention, enhanced neuronal differentiation, increased synaptic formation, and resulted in superior functional recovery compared with MicroSphere-based delivery. Mechanistically, RNA sequencing and experimental validation revealed that MicroRods promoted nuclear localization of β-catenin by inducing its dissociation from N-cadherin complexes. Inhibition of β-catenin nuclear transcription attenuated neuronal differentiation, confirming its critical role in geometry-mediated mechanotransduction. Collectively, this study identifies particle geometry as a key regulator of NSC fate and provides a effective strategy for enhancing neural regeneration after ischemic stroke.
- Open Access
- 10 March 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (3) , e70825
IL ‐ 17A Promotes NETs Formation via the PKCζ – ERK – ROS – PAD4 Pathway in a Mouse Model of Ischemic Stroke
Aims: Interleukin‐17A (IL‐17A) aggravates poststroke neurological damage and enhances neutrophil extracellular traps (NETs) formation, yet the underlying mechanism remains unclear. This study aimed to elucidate how IL‐17A regulates NETs generation after ischemic stroke. Methods: Using a mouse middle cerebral artery occlusion (MCAO) model, we administered the Peptidylarginine deiminase 4 (PAD4) inhibitor GSK484 or an IL‐17A‐neutralizing antibody (IL‐17mAb). Infarct volume and neurological function were assessed, and protein expression of PAD4, myeloperoxidase (MPO), citrullinated histones H3 (CitH3), protein kinase Cζ (PKCζ), and phosphorylated extracellular signal‐regulated kinase (p‐ERK) was evaluated. IL‐17A − / − mice and primary neutrophils were used to further validate the signaling pathway. Results: Inhibiting PAD4 with GSK484 can significantly reduce infarct size, improve neurological outcomes, and decrease PAD4, MPO, and CitH3 protein levels. Subsequently, we found that IL‐17mAb treatment can reduce the expression of PAD4, MPO, and CitH3 in the peri‐infarct area, as well as the expression of PKC‐ζ and p‐ERK. Similarly, the expression of PAD4 and CitH3 decreased in the peri‐infarct area of IL‐17A − / − MCAO mice. Finally, we verified IL‐17A induced PAD4 upregulation via the PKCζ–ERK–ROS axis in vitro. Conclusion: IL‐17A promotes NETs formation by upregulating PAD4 through the PKCζ–ERK–ROS pathway, exacerbating ischemic brain injury. Targeting this axis may offer a novel therapeutic strategy for stroke.
- 10 March 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (3) , e70825
Open AccessIL ‐ 17A Promotes NETs Formation via the PKCζ – ERK – ROS – PAD4 Pathway in a Mouse Model of Ischemic Stroke
Aims: Interleukin‐17A (IL‐17A) aggravates poststroke neurological damage and enhances neutrophil extracellular traps (NETs) formation, yet the underlying mechanism remains unclear. This study aimed to elucidate how IL‐17A regulates NETs generation after ischemic stroke. Methods: Using a mouse middle cerebral artery occlusion (MCAO) model, we administered the Peptidylarginine deiminase 4 (PAD4) inhibitor GSK484 or an IL‐17A‐neutralizing antibody (IL‐17mAb). Infarct volume and neurological function were assessed, and protein expression of PAD4, myeloperoxidase (MPO), citrullinated histones H3 (CitH3), protein kinase Cζ (PKCζ), and phosphorylated extracellular signal‐regulated kinase (p‐ERK) was evaluated. IL‐17A − / − mice and primary neutrophils were used to further validate the signaling pathway. Results: Inhibiting PAD4 with GSK484 can significantly reduce infarct size, improve neurological outcomes, and decrease PAD4, MPO, and CitH3 protein levels. Subsequently, we found that IL‐17mAb treatment can reduce the expression of PAD4, MPO, and CitH3 in the peri‐infarct area, as well as the expression of PKC‐ζ and p‐ERK. Similarly, the expression of PAD4 and CitH3 decreased in the peri‐infarct area of IL‐17A − / − MCAO mice. Finally, we verified IL‐17A induced PAD4 upregulation via the PKCζ–ERK–ROS axis in vitro. Conclusion: IL‐17A promotes NETs formation by upregulating PAD4 through the PKCζ–ERK–ROS pathway, exacerbating ischemic brain injury. Targeting this axis may offer a novel therapeutic strategy for stroke.
- 8 February 2026
- Published by Elsevier in Progress in Materials Science
- Vol. 160
Polymer modified cyclodextrin-based polyrotaxanes: From functionalization to applications
- 8 February 2026
- Published by Elsevier in Progress in Materials Science
- Vol. 160
Polymer modified cyclodextrin-based polyrotaxanes: From functionalization to applications
- Open Access
- 26 September 2025
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 10 (6) , e70060
Biomaterials‐driven stem cell therapy for tissue repair and functional rehabilitation after ischemic stroke
Ischemic stroke is a serious cerebrovascular disease with limited effective treatments. While stem cell therapy shows promise, ensuring cell survival and integration into neural networks remains a challenge. Recent research shows tissue engineering can greatly fix these flaws. Notably, we focus on the structure–activity relationship of biomaterials. How cell behavior can be most beneficially regulated by changes in the physical structure of the cell carrier itself is certainly a new perspective for cost saving and effectiveness increasing compared to the delivery of expensive biotrophic factors. However, there is a lack of research on biomaterials applied to ischemic stroke, especially in combination with stem cells. No biomaterial has even been approved for clinical trials in stroke. We provide a systematic summary of biomaterials‐driven stem cell therapy for ischemic stroke in terms of pathomechanisms, applications, and clinical translational challenges; we attempt to build a bridge from laboratory research to clinical translation in stroke treatment.
- 26 September 2025
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 10 (6) , e70060
Open AccessBiomaterials‐driven stem cell therapy for tissue repair and functional rehabilitation after ischemic stroke
Ischemic stroke is a serious cerebrovascular disease with limited effective treatments. While stem cell therapy shows promise, ensuring cell survival and integration into neural networks remains a challenge. Recent research shows tissue engineering can greatly fix these flaws. Notably, we focus on the structure–activity relationship of biomaterials. How cell behavior can be most beneficially regulated by changes in the physical structure of the cell carrier itself is certainly a new perspective for cost saving and effectiveness increasing compared to the delivery of expensive biotrophic factors. However, there is a lack of research on biomaterials applied to ischemic stroke, especially in combination with stem cells. No biomaterial has even been approved for clinical trials in stroke. We provide a systematic summary of biomaterials‐driven stem cell therapy for ischemic stroke in terms of pathomechanisms, applications, and clinical translational challenges; we attempt to build a bridge from laboratory research to clinical translation in stroke treatment.
- Open Access
- 8 September 2025
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (2) , 103-104
External Manual Carotid Compression for Cavernous Sinus Fistula
- 8 September 2025
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (2) , 103-104
Open AccessExternal Manual Carotid Compression for Cavernous Sinus Fistula
- Open Access
- 13 August 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (6) , 2286-2299
Nanomedicines and stroke: Advantages in chronic inflammation treatment and neural regeneration
Stroke can be categorized as ischemic and hemorrhagic on the basis of its origin. The pathophysiology following a stroke is complex, and is characterized by ongoing inflammation, neuronal injury, and the accumulation of reactive oxygen species in the brain, all of which reflect a dynamic process of change. This complexity hinders achievement of significant therapeutic outcomes with standard stroke treatment procedures, limiting post-stroke recovery. This review presents an innovative post-stroke therapeutic approach that utilizes nanomedicines to modify the cerebral microenvironment. It highlights the primary roles of chronic inflammation and nerve repair issues in causing prolonged impairment in stroke patients. Traditional therapies show limited effectiveness in achieving neuroprotection, immunoregulation, and neural regeneration during the subacute and chronic phases of stroke. Therefore, effective stroke management requires the use of specific therapeutic strategies tailored to the pathological characteristics of each phase. Various types of nanomedicines possess distinct physicochemical properties and can be selected on the basis of the specific therapeutic needs. Surface-modification technologies have significantly enhanced the ability of nanomedicines to penetrate the blood–brain barrier and improve their targeting capabilities in drug administration. However, the stability, biocompatibility, and long-term safety of nanomedicines require further optimization for clinical application. Nanomedicines represent a novel approach to stroke treatment through targeted delivery and multifaceted regulatory mechanisms. These medicines provide distinct advantages, particularly in addressing chronic inflammation and promoting nerve regeneration. As a result, nanomedicines are expected to significantly improve rehabilitation outcomes and quality of life for stroke patients in the future, emerging as a crucial modality for stroke treatment.
- 13 August 2025
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (6) , 2286-2299
Open AccessNanomedicines and stroke: Advantages in chronic inflammation treatment and neural regeneration
Stroke can be categorized as ischemic and hemorrhagic on the basis of its origin. The pathophysiology following a stroke is complex, and is characterized by ongoing inflammation, neuronal injury, and the accumulation of reactive oxygen species in the brain, all of which reflect a dynamic process of change. This complexity hinders achievement of significant therapeutic outcomes with standard stroke treatment procedures, limiting post-stroke recovery. This review presents an innovative post-stroke therapeutic approach that utilizes nanomedicines to modify the cerebral microenvironment. It highlights the primary roles of chronic inflammation and nerve repair issues in causing prolonged impairment in stroke patients. Traditional therapies show limited effectiveness in achieving neuroprotection, immunoregulation, and neural regeneration during the subacute and chronic phases of stroke. Therefore, effective stroke management requires the use of specific therapeutic strategies tailored to the pathological characteristics of each phase. Various types of nanomedicines possess distinct physicochemical properties and can be selected on the basis of the specific therapeutic needs. Surface-modification technologies have significantly enhanced the ability of nanomedicines to penetrate the blood–brain barrier and improve their targeting capabilities in drug administration. However, the stability, biocompatibility, and long-term safety of nanomedicines require further optimization for clinical application. Nanomedicines represent a novel approach to stroke treatment through targeted delivery and multifaceted regulatory mechanisms. These medicines provide distinct advantages, particularly in addressing chronic inflammation and promoting nerve regeneration. As a result, nanomedicines are expected to significantly improve rehabilitation outcomes and quality of life for stroke patients in the future, emerging as a crucial modality for stroke treatment.
- 10 April 2025
- Published by Elsevier in Experimental Neurology
- Vol. 389, 115255
Intermittent theta burst stimulation regulates microglial polarization through Cry1 to enhance neuroplasticity for stroke recovery
- 10 April 2025
- Published by Elsevier in Experimental Neurology
- Vol. 389, 115255
Intermittent theta burst stimulation regulates microglial polarization through Cry1 to enhance neuroplasticity for stroke recovery
- 28 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113931
Inhibition of HIF-1α ameliorates pulmonary fibrosis by suppressing M2 macrophage polarization through PRMT1/STAT6 signals
- 28 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113931
Inhibition of HIF-1α ameliorates pulmonary fibrosis by suppressing M2 macrophage polarization through PRMT1/STAT6 signals
- Open Access
- 2 August 2024
- Published by Elsevier in Materials Today Bio
- Vol. 28, 101177
Curcumin loaded hydrogel with double ROS-scavenging effect regulates microglia polarization to promote poststroke rehabilitation
- 2 August 2024
- Published by Elsevier in Materials Today Bio
- Vol. 28, 101177
Open AccessCurcumin loaded hydrogel with double ROS-scavenging effect regulates microglia polarization to promote poststroke rehabilitation